Dive Summary:
- FMC Corporation acquired all shares of Epax in a deal valued at around $345 million.
- Epax manufactures premium grade omega-3 fatty acid concentrates used in nutraceuticals, pharmaceuticals and foods.
- The deal includes Epax's production facilities in Alesund, Norway, and Seal Sands, UK.
From the press release:
... The market for supply of Omega-3 fatty acids is $2.1 billion per year, projected to grow 12 percent to 15 percent annually. Consumer awareness about cardiovascular, brain, and numerous other health benefits of Omega-3—supported by years of scientific studies and regulatory organizations—continues to drive strong demand, especially for high purity, highly concentrated products.
"For decades, FMC has been known in the pharmaceutical and food markets as a leader in functional ingredients—highly focused on customer needs, product quality and consistency, and customized innovation," said Mike Smith, vice president and global business director,
